APA (7th ed.) Citation

W, H., F, S., P, C., CS, S., Y, C., KL, G., . . . P, C. (2022). Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. Frontiers in pharmacology, 13, 974423. https://doi.org/10.3389/fphar.2022.974423

Chicago Style (17th ed.) Citation

W, Huang, et al. "Development of a Pediatric Physiologically-based Pharmacokinetic Model to Support Recommended Dosing of Atezolizumab in Children with Solid Tumors." Frontiers in Pharmacology 13 (2022): 974423. https://doi.org/10.3389/fphar.2022.974423.

MLA (9th ed.) Citation

W, Huang, et al. "Development of a Pediatric Physiologically-based Pharmacokinetic Model to Support Recommended Dosing of Atezolizumab in Children with Solid Tumors." Frontiers in Pharmacology, vol. 13, 2022, p. 974423, https://doi.org/10.3389/fphar.2022.974423.